What is the recommended dupilumab (Dupixent) dosing, monitoring, and contraindications for adults with chronic rhinosinusitis, especially with nasal polyps, refractory to intranasal corticosteroids or surgery?

Dupilumab for Chronic Rhinosinusitis with Nasal Polyps

For adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) refractory to intranasal corticosteroids or surgery, dupilumab 300 mg subcutaneously every 2 weeks is the recommended biologic therapy, added to continued intranasal corticosteroid treatment. 1

Patient Selection & Indications

Dupilumab is indicated specifically for adults with CRSwNP, not for CRS without polyps. 2 The 2025 American Academy of Otolaryngology guidelines explicitly recommend against routine biologic use in CRS without polyps due to lack of evidence in this population 2.

Ideal candidates meet the following criteria 3:

• Severe CRSwNP confirmed by nasal endoscopy showing bilateral polyps 2
• Inadequate response to intranasal corticosteroids despite appropriate use 4
• Type 2 inflammation markers (elevated blood eosinophils, IgE, or FeNO) 3
• Prior sinus surgery or need for systemic corticosteroids 3
• Clinically significant loss of smell 3

Dupilumab is the first-choice biologic for CRSwNP based on superior efficacy across all major outcomes compared to mepolizumab and omalizumab. 5, 3

Dosing & Administration

The FDA-approved regimen is 300 mg subcutaneously every 2 weeks with no loading dose for CRSwNP. 1 This differs from other indications where loading doses are used 1.

Administration details 3, 1:

• Inject into thigh, abdomen (avoiding 2 inches around navel), or upper arm (if caregiver administers) 1
• Rotate injection sites with each dose 1
• First 1-2 injections should be clinic-administered for training and anaphylaxis monitoring 3
• Subsequent doses may be self-administered with auto-injector 3
• Allow 45 minutes for room temperature equilibration before injection 1

Intranasal corticosteroids must be continued as background therapy when initiating dupilumab. 4, 3, 6 The pivotal trials used mometasone furoate 100 µg per nostril twice daily as standard of care 4, 7.

Treatment Duration & Response Assessment

A minimum of 24 weeks is required to assess full clinical response, with optimal outcomes demonstrated at 52 weeks. 4, 3, 8 The phase 3 LIBERTY NP SINUS trials showed continued improvement through 52 weeks 4, 8.

Discontinuation at 24 weeks leads to disease recurrence; therefore, treatment should be continued indefinitely for sustained control. 3, 9 One study showed that extending intervals to every 4 weeks after achieving maximal response maintained control without recurrence 10, though this diverges from FDA approval and requires further validation 10.

Baseline assessments should include 3:

• Endoscopic nasal polyp score (0-8 scale) 4, 3
• Lund-Mackay CT score (0-24 scale) 4, 3
• SNOT-22 quality-of-life score (0-110 scale) 4, 3
• University of Pennsylvania Smell Identification Test (UPSIT, 0-40 scale) 4, 3
• Nasal congestion score (0-3 scale) 3
• For comorbid asthma: spirometry (FEV₁), Asthma Control Questionnaire, and exacerbation history 3

Re-evaluation at 16-24 weeks determines therapeutic response. 3 Clinical remission—defined as 12 months without exacerbations requiring oral corticosteroids, no need for surgery, no anosmia, SNOT-22 <20, and Lund-Mackay score <10—was achieved in 11% of patients in real-world studies 9.

Efficacy Outcomes

Dupilumab demonstrates clinically meaningful improvements across all major endpoints 4, 8:

Nasal polyp score: Mean reduction of -1.9 points versus -0.3 with placebo (difference -1.6,95% CI -2.4 to -0.7) 4

SNOT-22 quality of life: Mean improvement of -19.61 points (95% CI -22.53 to -16.69), exceeding the minimal clinically important difference of 8.9 points 4

Nasal congestion: Mean reduction of -0.86 points (95% CI -0.98 to -0.75) 4

Smell restoration: Mean UPSIT improvement of 10.83 points (95% CI 9.59 to 12.08) 4

Lund-Mackay CT score: Mean reduction of -7.44 points in SINUS-24 and -5.13 points in SINUS-52 8

At 24 weeks, dupilumab significantly reduces the need for systemic corticosteroids and sinus surgery compared to placebo. 3, 8 These benefits occur regardless of baseline eosinophil count, prior surgery status, or presence of NSAID-exacerbated respiratory disease 3, 11.

Comorbid Asthma Benefits

In patients with comorbid asthma (present in approximately 80% of severe CRSwNP cases), dupilumab improves lung function by a mean of +0.21 L FEV₁ and enhances asthma control. 3, 11, 9 However, comorbid asthma is associated with larger nasal polyps both before and after treatment, and slightly lower rates of achieving clinical remission (7.3% versus 11% overall) 9.

Safety Profile & Monitoring

Dupilumab is well-tolerated with no increase in serious adverse events versus placebo. 3, 8 The most common adverse events are actually less frequent than with placebo and include 4, 8:

• Nasopharyngitis 3, 8
• Headache 3, 8
• Epistaxis (reported in clinical studies) 3

Monitor for conjunctivitis, which occurs in approximately 2% of CRSwNP patients treated with dupilumab. 3 This is lower than the 10-15% rate seen in atopic dermatitis patients 3.

Track systemic corticosteroid use and any need for rescue sinus surgery as secondary outcome measures 3.

Contraindications & Precautions

Complete age-appropriate vaccinations before initiating dupilumab. 1 The FDA label recommends considering vaccination completion prior to treatment 1.

Do not inject into skin that is tender, damaged, bruised, or scarred 1.

Positioning Among Biologics

Network meta-analyses establish dupilumab as the first-choice biologic for CRSwNP due to superior efficacy across nasal polyp size, SNOT-22, nasal congestion, and smell restoration compared to omalizumab and mepolizumab. 5, 3

Alternative biologics may be considered in specific circumstances 5, 3:

• Omalizumab: Preferred for females planning pregnancy 3
• Mepolizumab: Alternative for patients with highly eosinophilic asthma or eosinophilic granulomatosis with polyangiitis (EGPA), as dupilumab may increase peripheral eosinophilia and potentially unmask EGPA 5

Common Pitfalls to Avoid

Do not discontinue intranasal corticosteroids when starting dupilumab—the efficacy data are based on add-on therapy to continued INCS 4, 3, 6.

Do not assess treatment failure before 16-24 weeks—early discontinuation leads to suboptimal outcomes as full therapeutic benefit requires this duration 3.

Do not use dupilumab for CRS without nasal polyps—current guidelines recommend against this due to absence of evidence in this population 2.

Do not assume all CRSwNP patients need biologics first—patients with low disease burden who have not tried INCS or surgery may prefer less invasive options 5.